For Immediate Release

Chicago, IL – July 9, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Research In Motion (RIMM), Apple (AAPL), Palm (PALM), GlaxoSmithKline Plc (GSK) and Merck (MRK).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

Apple to Grab Smartphone Share

According to a recent survey, the mobile handset manufacturing industry continues to witness increased demand for smartphones. Around 37% of the sample population already owns a smartphone, while 14.4% plans to buy the product within next 3 months.

The major benefit from this increased demand for

...

On July 7, GlaxoSmithKline Plc (GSK) announced that data from a large efficacy study showed that Cervarix, its human papillomavirus (HPV) vaccine, is highly effective in protecting against the two most common cervical cancer-causing HPV types, 16 and 18. Cervarix provided 92.9% protection against cervical pre-cancers associated with HPV 16 or 18.

HPV types 16 and 18 account for an estimated 70% of cervical cancer cases and can lead to vulvar and vaginal cancers. The study also showed that Cervarix provides cross-protection against HPV types 31, 33 and 45, which are most likely to lead to cervical cancer after 16 and 18. Results from this study, which was conducted with 18,644 women aged 15-25, were published in The Lancet.

We expect Cervarix to be a significant contributor to the company’s topline over the next several years. Cervarix is already approved in 97 countries across the world, including the

...